Related Experiment Videos
[Bone marrow transplantation for leukemia: long term outcome]
Christèle Ferry1, Gérard Socie
1Service d'hématologie greffe de moelle, hôpital Saint-Louis, 1 avenue Claude-Vellefaux, 75475 Paris, France.
Bulletin Du Cancer
|September 6, 2003
Summary
Allogeneic stem cell transplantation offers a cure for high-risk blood cancers. Long-term follow-up is crucial for managing potential complications and ensuring good quality of life post-transplant.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Context:
- Allogeneic stem cell transplantation (SCT) is a curative option for high-risk malignant hematopoietic disorders.
- Significant advancements in supportive care and graft-versus-host disease (GVHD) prophylaxis have improved patient outcomes.
- While late relapses are infrequent beyond two years, long-term monitoring is essential.
Purpose:
- To highlight the critical need for prolonged follow-up after allogeneic SCT.
- To discuss the spectrum of potential long-term complications following transplantation.
- To evaluate the impact of these complications on patient quality of life.
Summary:
- Allogeneic SCT is a potentially curative treatment for hematologic malignancies.
- Long-term complications, including infections, secondary malignancies, and chronic GVHD, can be life-threatening or impair quality of life.
- Commonly reported side effects such as fatigue, sleep disturbances, and sexual dysfunction significantly affect daily living.
Impact:
- Despite potential long-term adverse effects, most patients report a good quality of life post-transplant.
- The benefits of allogeneic SCT are generally considered to outweigh the late-occurring complications.
- This underscores the importance of comprehensive long-term patient management and support.